News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,710 Results
Type
Article (42375)
Company Profile (436)
Press Release (672899)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (208774)
Career Advice (2022)
Deals (36011)
Drug Delivery (104)
Drug Development (83588)
Employer Resources (173)
FDA (16444)
Job Trends (15106)
News (352858)
Policy (33091)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (88)
Alliances (50975)
ALS (99)
Alzheimer's disease (1435)
Antibody-drug conjugate (ADC) (147)
Approvals (16425)
Artificial intelligence (278)
Autoimmune disease (26)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (299)
Cancer (2374)
Cardiovascular disease (191)
Career advice (1690)
Career pathing (30)
CAR-T (161)
Cell therapy (456)
Cervical cancer (20)
Clinical research (67870)
Collaboration (899)
Company closure (2)
Compensation (566)
Complete response letters (24)
COVID-19 (2650)
CRISPR (47)
C-suite (262)
Cystic fibrosis (106)
Data (2335)
Decentralized trials (2)
Denatured (29)
Depression (52)
Diabetes (280)
Diagnostics (6438)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (111)
Drug shortages (26)
Duchenne muscular dystrophy (103)
Earnings (88233)
Editorial (43)
Employer branding (21)
Employer resources (147)
Events (116199)
Executive appointments (758)
FDA (17828)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (802)
Gene editing (119)
Generative AI (20)
Gene therapy (337)
GLP-1 (756)
Government (4516)
Grass and pollen (4)
Guidances (150)
Healthcare (19150)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (136)
Indications (30)
Infectious disease (2797)
Inflammatory bowel disease (150)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (99)
Interviews (312)
IPO (16804)
IRA (43)
Job creations (3704)
Job search strategy (1434)
Kidney cancer (10)
Labor market (43)
Layoffs (506)
Leadership (18)
Legal (7987)
Liver cancer (77)
Lung cancer (332)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (332)
MASH (76)
Medical device (13533)
Medtech (13538)
Mergers & acquisitions (19771)
Metabolic disorders (738)
Multiple sclerosis (84)
NASH (19)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (2021)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (40)
Obesity (394)
Opinion (223)
Ovarian cancer (82)
Pain (96)
Pancreatic cancer (89)
Parkinson's disease (157)
Partnered (21)
Patents (244)
Patient recruitment (116)
Peanut (47)
People (58728)
Pharmaceutical (86)
Pharmacy benefit managers (20)
Phase I (21326)
Phase II (29957)
Phase III (22136)
Pipeline (1369)
Policy (155)
Postmarket research (2601)
Preclinical (9155)
Press Release (67)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (409)
Real estate (6015)
Recruiting (66)
Regulatory (22791)
Reports (47)
Research institute (2416)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (141)
Series B (93)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3765)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (48)
The Weekly (49)
Vaccines (717)
Venture capitalists (44)
Weight loss (257)
Women's health (38)
Worklife (17)
Date
Today (36)
Last 7 days (950)
Last 30 days (3111)
Last 365 days (33417)
2025 (11992)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (59)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39298)
Australia (6538)
California (6512)
Canada (2073)
China (547)
Colorado (278)
Connecticut (292)
Delaware (159)
Europe (85953)
Florida (950)
Georgia (213)
Idaho (57)
Illinois (565)
India (25)
Indiana (322)
Iowa (12)
Japan (173)
Kansas (109)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (939)
Massachusetts (4923)
Michigan (225)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (67)
New Hampshire (67)
New Jersey (1821)
New Mexico (30)
New York (1820)
North Carolina (1054)
North Dakota (8)
Northern California (2838)
Ohio (211)
Oklahoma (14)
Oregon (38)
Pennsylvania (1435)
Puerto Rico (13)
Rhode Island (34)
South America (1111)
South Carolina (25)
South Dakota (1)
Southern California (2440)
Tennessee (105)
Texas (964)
United States (24488)
Utah (191)
Virginia (156)
Washington D.C. (66)
Washington State (585)
West Virginia (3)
Wisconsin (57)
715,710 Results for "chinook therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioForest
Chinook Therapeutics to Present at Upcoming May 2023 Investor Conferences
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
April 27, 2023
·
1 min read
BioForest
Chinook Therapeutics to Present at Upcoming April 2023 Investor Conferences
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
April 11, 2023
·
1 min read
BioForest
Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Chinook Therapeutics, Inc. today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 3:20 pm ET, as well as 1x1 meetings.
March 7, 2023
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
BioForest
Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced that Chinook management is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 11:20 am ET, as well as 1x1 meetings.
February 7, 2023
·
1 min read
Drug Development
Novartis’ $3.2B Chinook Buy Pays Off with Promising Phase III IgAN Data
Following the recent Chinook Therapeutics acquisition, the Novartis experimental IgA nephropathy therapeutic atrasentan significantly reduced protein in the urine of patients compared to placebo.
October 31, 2023
·
2 min read
·
Tristan Manalac
BioForest
Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.
March 28, 2023
·
1 min read
Business
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.
May 9, 2023
·
11 min read
BioForest
Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023
Chinook Therapeutics, Inc. today announced presentations at the ISN World Congress of Nephrology 2023 from March 30 – April 2, 2023 in Bangkok, Thailand.
March 23, 2023
·
3 min read
Business
Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors.
April 13, 2023
·
5 min read
1 of 71,571
Next
